Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
The Developing Nearby Food Development and Its Advantages- Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- These Are the Journalists Israel Has Killed Since the Start of the Iran War
- One dead, six wounded in various crime-related shootings in Israel over the weekend
- Financial plan Cordial Home Redesigns That Add Worth
- Step by step instructions to Recognize the Distinction Between Lab Jewels and Precious stone Simulants
- Israel faces widespread condemnation as NGO ban comes into effect
- IDF Givati Brigade soldier arrested, charged in suspected Iran espionage
- The Best 20 Tunes that Characterized an Age
